Drilling Expedited at Tolmer High-Grade Silver Discovery
Follow-up drilling expedited for March 2025 Tolmer 'silver zone' discovery; single line of 7 'discovery holes' returned 3 globally significant high-grade silver assays, including:1
ADELAIDE, AUSTRALIA / ACCESS Newswire / May 11, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to confirm that follow-up drilling has been expedited at its South Australian Tarcoola Gold Project (Tarcoola), where Tolmer's new 'silver zone' was discovered in a line of seven discovery holes returning three globally significant assays.1 Bullion Drilling has been engaged as driller, with drilling expected to start next week.
Commenting on expedited Tolmer drilling plans, Barton MD Alexander Scanlon said:
"We are wasting no time following up our new Tolmer high-grade silver discovery, confirmed just 6 weeks ago. The original line of seven drill holes has already returned three silver assays which featured in various 'global Top 10' rankings. These are unusually high-grade for Australia, so we are excited to map this zone out quickly."
Authorised by the Managing Director of Barton Gold Holdings Limited.
For further information, please contact:
About Barton Gold
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.7Moz Au & 3.1Moz Ag JORC Mineral Resources (64.0Mt @ 0.83 g/t Au), brownfield mines, and 100% ownership of the region's only gold mill in the renowned Gawler Craton of South Australia.*
Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).
The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company's Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company's website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons' findings are presented have not been materially modified from the previous announcements.
Cautionary Statement Regarding Forward-Looking Information
This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "expect", "target" and "intend" and statements than an event or result "may", "will", "should", "would", "could", or "might" occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performance[2]: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%[3] and on track to meet full year guidance[4]. Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable. Adjusted EBITDA[5] of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment. $81.6 million invested into R&D, a 47% increase year-over-year. Investment was primarily focused on late-stage assets in the therapeutics and precision medicine pipeline. Full year R&D investment guidance is maintained[6]. Loss before tax of $4.8 million includes $12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cost of $9.5 million (2024 $2.4 million) following RLS acquisition. Positive operating net cash flow of $17.7 million, cash balance $207.2 million following $241. 8 million of strategic merger and acquisition (M&A) investment. Telix Precision Medicine: Commercial business delivers profitable growth Precision Medicine segment revenue up by 30% compared to H1 2024, driven by continued increase in Illuccix dose volumes. Illuccix gross margin remains stable at 64%. Adjusted EBITDA up by 24% year-over-year to $104.6 million. Selling and marketing expenses of $40.9 million, reflecting incremental investment in commercial infrastructure for new product launches (Illuccix European launches and Gozellix®, Zircaix® and Pixclara®[7]). Telix Manufacturing Solutions (TMS): Investment in infrastructure to scale operations and meet future demand TMS segment includes RLS Radiopharmacies (RLS, U.S.[8]), IsoTherapeutics (TX, U.S.), and TMS facilities in Sacramento (CA, U.S.), Brussels South (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly augmented global production and manufacturing footprint to support clinical and commercial operations. Operating expenses of $30.5 million for the segment include $14.9 million for RLS business and $15.6 million to support start-up and integration activities (ex-RLS). RLS – the core revenue driver in TMS – reported $109.5 million of revenue, which includes $79.0 million from third-party PET[9] and SPECT[10] product sales and distribution service fees, and $30.5 million inter-segment revenue. RLS delivered an Adjusted EBITDA loss of $1.1 million. RLS operating loss includes $6.3 million of depreciation and amortization. Telix Therapeutics: Reinvesting earnings to accelerate late-stage pipeline Of the total R&D investment, 54% ($43.9 million) was invested in the therapeutics pipeline. Milestones achieved include: TLX591 (177Lu-rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the Phase 3 study in advanced metastatic castration resistant prostate cancer (mCRPC). The trial has received regulatory approval to proceed in Australia, China, Canada, New Zealand, Turkey and Japan. TLX592 (225Ac-PSMA-RADmAb): Approval to commence a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced mCRPC. TLX101 (131I-iodofalan, or 131I-IPA): Approval to commence IPAX BrIGHT, an international pivotal trial, to commence at Australian sites initially. TLX090 (153Sm-DOTMP): Investigational New Drug (IND) application approved for a Phase 1 bridging study for Telix's therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone. Commentary Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result: "Telix continues to deliver strong revenue growth while building a foundation for the future. The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline. These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success. To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the PSMA portfolio." Summary Group financial resultsH1 2025 H1 2024 US$M US$M Revenue 390.4 239.6 Cost of sales (181.8) (82.4) Gross profit 208.6 157.2 Research and development (R&D) (81.6) (55.4) Selling and marketing (49.0) (24.6) Manufacturing and distribution (18.8) (8.4) General and administration (47.7) (39.2) Other losses (net) (1.1) (1.9) Operating profit 10.4 27.7 Finance income 3.6 0.9 Finance costs (18.8) (5.7) (Loss)/profit before tax (4.8) 22.9 Adjusted EBITDA 21.1 37.1 Cash from operating activities 17.7 23.3 Guidance Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million[11]. Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS[12]. Telix confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024. lnvestor call An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025). Participants can register for the webcast by clicking here: or the teleconference here: About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations (Global)Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate Communications Email: Telix Investor Relations (U.S.)Ms. Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate Communications Email: Guidance Disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix's ability to protect its patents and other intellectual property. This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved. [1]. See summary Group financial results table at end of this document.[2]. Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).[3]. All comparisons to H1 2024 results.[4]. FY 2025 revenue guidance of US$770 million to US$800 million.[5]. Earnings before interest, tax, depreciation and amortization.[6]. Increased investment range for FY 2025 expected to be 20% to 25% compared to FY 2024.[7]. Launch and brand names subject to final regulatory approval.[8]. RLS network is comprised of 28 locations across the U.S.[9]. Positron emission tomography.[10]. Single photon emission computed tomography.[11]. Refer to ASX disclosures 20 February 2025.[12]. See Guidance Disclaimer for further information. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
How to Play Nvidia Stock as the Plot Over Its China Business Thickens
It's hard to keep Nvidia (NVDA), the world's biggest company and the first one to command a $4 trillion market cap, out of the news cycle. Over the last few weeks, Nvidia has been in the news regarding its China business, and most recently, Reuters reported that the company is developing a new chip for China. In this article, we'll look at some of the recent developments related to Nvidia's China business and examine the company's outlook. More News from Barchart Should You Buy the Pullback in Palantir Stock Today? The Quantum Computing Race Is On: These 2 Stocks Appear Poised to Lead As SoFi Launches International Money Transfer Services, How Should You Play SOFI Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Successive U.S. Governments Have Clamped Down on NVDA's Exports to China Why Nvidia's chips have been the building blocks for artificial intelligence (AI) models, they have also added a new dimension to the U.S.-China rivalry. President Joe Biden's administration imposed restrictions on Nvidia's export of advanced AI chips to China, citing fears over their dual military use. President Donald Trump's administration went a step further and blocked the exports of Nvidia's H20 chips to China. Nvidia had specifically designed these chips for China to meet the guidelines set by the U.S. government, and after the ban, it booked a charge of $4.5 billion in the first quarter of its fiscal 2026. Why Is China an Important Market for Nvidia? China was once Nvidia's second-largest market, but U.S. export control restrictions have taken a toll on its business there. During the fiscal Q1 2026 earnings call in May, CFO Collete Kress said, 'Losing access to the China AI accelerator market, which we believe will grow to nearly $50 billion, would have a material adverse impact on our business going forward and benefit our foreign competitors in China and worldwide.' Nvidia CEO Jensen Huang has said multiple times that the export restrictions would only fuel chip innovation in China as rivals, particularly Huawei, catch up. While the Trump administration has allowed Nvidia to resume H20 exports to China, the company will need to share 15% of its China revenues with the U.S. government. The unusual agreement left markets perplexed, as the ostensible reason the U.S. banned exports of advanced AI chips to China was because of national security concerns, and a cut in revenues does not help address that. Many see legal challenges to the revenue share agreement, and separately, lawmakers across the political divide have been critical of the export resumption. Reports suggest that Nvidia is developing a new AI chip for China. Tentatively named B30A, it is said to be based on the company's Blackwell architecture and would be more powerful than the H20, which is currently its most advanced chip sold in China. In its response to the reports of the new chip for China, Nvidia said, 'We evaluate a variety of products for our roadmap, so that we can be prepared to compete to the extent that governments allow.' It emphasized, 'Everything we offer is with the full approval of the applicable authorities and designed solely for beneficial commercial use.' China Does Not Looks Too Welcoming of Nvidia's H20 Meanwhile, the Chinese government hasn't been too welcoming of the H20 chip these days and has cautioned domestic companies against using these over fears of a U.S. government 'backdoor.' Nvidia has denied any such claims, but it remains to be seen whether Chinese companies defy the government warning to buy the H20. NVDA Stock Forecast Wall Street analysts are meanwhile not too perturbed by these concerns and have started raising Nvidia's target price ahead of its upcoming earnings report. TD Cowen raised Nvidia's target price to $235 and sees a 'clean narrative' for the stock despite concerns over its China business. Cantor Fitzgerald raised its target price from $200 to $240 as analyst C.J. Muse sees 'seemingly insatiable' demand for AI compute. Mizuho raised its target price from $192 to $205, while Morgan Stanley raised its from $200 to $206. All three brokerages expect Nvidia to beat consensus estimates when it reports its fiscal Q2 2026 earnings next week. Should You Buy NVDA Stock? While Nvidia's China business is shrouded in uncertainty, the company's non-China business is doing incredibly well. The June quarter earnings calls of other Big Tech companies, which include the so-called hyperscalers, showed that companies are not slowing down their AI capex, and if anything, they are doubling down amid early signs of monetization. Sovereign AI is yet another growth driver for Nvidia, as, given the growing importance of AI, major countries want to have more control over the technology. Huang has been globe-trotting for a reason and has been pitching sovereign AI on his trips to the Middle East and the European Union this year. Nvidia trades at a forward price-earnings (P/E) multiple of 45.2x, which does not look bloated in the context of the strong earnings growth that the company brings to the table. Moreover, markets never fully priced in a normal business environment for Nvidia in China, and any sales in the country would be incremental to Nvidia's top line and bottom line despite the 15% revenue share with the U.S. government. Overall, while the noise over the China business might put pressure on Nvidia stock in the near term, I continue to stay invested in the company and will use any further weakness to add to my positions. On the date of publication, Mohit Oberoi had a position in: NVDA. All information and data in this article is solely for informational purposes. This article was originally published on Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Yahoo
an hour ago
- Yahoo
Perseus Updates Mineral Resource and Reserve Estimates
perth, Aug. 21, 2025 (GLOBE NEWSWIRE) -- PERSEUS MINING UPDATES MINERAL RESOURCES AND ORE RESERVE ESTIMATES Executive Summary Perth, Western Australia/August 21, 2025/Perseus Mining Limited (ASX/TSX: PRU) is pleased to update estimates of its Mineral Resources and Ore Reserves as of 30 June 2025. A summary of the release is included below. For the full release please refer to or The Perseus Group's Measured and Indicated (M&I) Mineral Resources now total 7.8 Moz gold (Table 1) while Proved and Probable Ore Reserves total 5.0 Moz gold (Table 2). Not included in these estimates, is the Foreign/Historical Estimate for the Meyas Sand Gold Project (MSGP, formerly Block 14) including Indicated Mineral Resources1 consisting of 3.3 Moz Au (Table 3) and a Probable Mineral Reserve1 of 2.9 Moz gold (Table 4). The sources of change underlying the 2.1 Moz gold increase in Perseus's estimate of Ore Reserves against those reported at 30 June 2024 are presented in Error! Reference source not found.. As part of its annual planning cycle, the Company has reassessed the growth opportunities available within its portfolio with the approach of optimising the portfolio rather than focussing on fixed investment targets for each asset. In this way, the Company has sought to find the balance between investment in growth opportunities and the cash margin generated by the ESTIMATES PROJECT MEASURED RESOURCES INDICATED RESOURCES MEASURED & INDICATED RESOURCES INFERRED RESOURCES QUANTITY GRADE GOLD QUANTITY GRADE GOLD QUANTITY GRADE GOLD QUANTITY GRADE GOLD MT G/T GOLD '000 OZ MT G/T GOLD '000 OZ MT G/T GOLD '000 OZ MT G/T GOLD '000 OZ Edikan 13.1 0.96 407 37.7 1.02 1,236 50.8 1.01 1,644 7.8 1.5 367 Sissingué3 1.5 1.18 56 5.3 1.85 317 6.8 1.71 373 0.2 1.2 7 Yaouré 11.5 0.79 293 42.6 1.68 2,301 54.1 1.49 2,594 16.9 1.8 982 Nyanzaga - - - 74.2 1.33 3,162 74.2 1.33 3,162 15.0 1.2 584 Total 26.1 0.90 756 159.8 1.37 7,017 185.9 1.30 7,773 39.9 1.5 1,940PROJECT PROVED PROBABLE PROVED & PROBABLE QUANTITY GRADE GOLD QUANTITY GRADE GOLD QUANTITY GRADE GOLD MT G/T GOLD '000 OZ MT G/T GOLD '000 OZ MT G/T GOLD '000 OZ Edikan 8.6 0.91 250 21.1 1.08 730 29.7 1.03 980 Sissingué3 0.8 1.42 38 2.9 2.14 199 3.7 1.98 237 Yaouré 11.5 0.79 293 19.8 1.81 1,151 31.3 1.44 1,444 Nyanzaga - - - 52.0 1.40 2,342 52.0 1.40 2,342 Total 20.9 0.86 581 95.8 1.44 4,422 116.7 1.33 5,003 Notes for Table 1 and Table 2: 1 Refer to Notes to individual tables of Mineral Resources and Ore Reserves in respect of each project presented below. 2 Mineral Resources are inclusive of Ore Reserves. 3 Sissingué Mineral Resources and Ore Reserves include the Fimbiasso and Bagoé Projects in addition to the Sissingué Gold Mine. 4 The Company holds 90% of Edikan Gold Mine (EGM) and Yaouré Gold Mine (YGM), 86% of Sissingué Gold Mine (SGM) except Bagoé at 90%, and 80% of Nyanzaga Gold Project (NGP). 5 Excludes Foreign/Historical Estimates Foreign/historical estimatesTYPE INDICATED5 INFERRED Mt Au g/t Ag g/t Au koz Ag koz Mt Au g/t Ag g/t Au koz Ag koz Oxide 10.2 1.35 1.49 443 487 1.1 1.0 1.2 34 41 Trans. 13.4 1.22 1.33 527 575 1.5 1.0 1.2 50 57 Fresh 56.3 1.31 1.82 2,371 3,296 15.9 1.2 1.6 626 838 TOTAL 79.9 1.30 1.70 3,342 4,358 18.5 1.2 1.6 711 936 Notes for Table 3: Based on September 2018 estimates of Galat Sufar South and Wadi Doum Mineral Resources by MPR Geological Consultants Pty Ltd. 0.6 g/t cut-off grade applied to all material types. Estimates are not depleted for artisanal mining, the impact of which is not considered material. Galat Sufar South Mineral Resource estimates are truncated at 350 m depth, with around 90% of Indicated and Inferred resources occurring at depths of less than 240 and 300 m respectively. Wadi Doum estimates extend to around 255 m depth, with around 90% of Indicated and Inferred resources occurring at depths of less than 115 m and 190 m respectively. The depth limits imposed on the estimates are considered to largely confine the estimates to material with reasonable prospects of eventual economic extraction. Indicated Mineral Resources are inclusive of Mineral Reserves. Rounding of numbers to appropriate precisions may have resulted in apparent AREA CLASSIFICATION OXIDE TRANSITIONAL FRESH TOTAL '000 tonnes Au g/t '000 tonnes Au g/t '000 tonnes Au g/t '000 tonnes Au g/t Main Probable 4,347 1.27 5,088 1.19 13,488 1.31 22,923 1.28 East Probable 8,302 0.89 11,236 0.89 30,729 1.05 50,267 0.99 North East Probable 1,606 0.84 2,192 0.85 367 0.90 4,166 0.85 Total GSS Probable 14,255 1.00 18,516 0.97 44,584 1.13 77,356 1.07 Wadi Doum Probable 527 1.90 119 2.37 1,941 2.49 2,588 2.36 Block 14 Total Probable 14,783 1.03 18,635 0.98 46,525 1.19 79,943 1.11 Notes for Table 4: Based on Mineral Reserve Statement 7 November 2018. CIM Definition Standards were followed for the classification of Mineral Reserves. Mineral Reserves were optimised using a gold price of US$1,100/oz. Mining Cut-off grades vary between 0.32 g/t and 0.90 g/t. Rounding of numbers to appropriate precisions may have resulted in apparent inconsistencies. Perseus's Mineral Resource Estimates The Perseus Group's total M&I Mineral Resources reported as at 30 June 2025 are estimated to be 185.9 Mt grading 1.30 g/t gold, containing 7.8 Moz of gold, compared with the estimate of 30 June 2024 of 115.9 Mt grading at 1.31 g/t Au for 4.9 Moz of gold. The Mineral Resource Statement accounts for mining depletion of in-situ Mineral Resources and is reported inclusive of Ore Reserves. Inferred Resources are 39.9 Mt grading at 1.5 g/t Au for 1.9 Moz of gold, compared with the estimate of 30 June 2024 of 24.1 Mt grading at 1.6 g/t Au for 1.3 Moz of gold. Tonnes are reported as dry metric tonnes. All tabulated tonnes, grade and metal have been rounded to reflect appropriate precision in the estimate and may cause some discrepancies in totals. The Foreign/Historical Estimate for the MSGP Mineral Resource in Northern Sudan, announced on 28 February 2022 (see news release titled 'Perseus enters into agreement to acquire Orca Gold Inc.') is stated in the 'Foreign/Historical Estimate' subsection of this report and is reported separately from the Group's Mineral Resources detailed below. The Group Mineral Resource estimates are reported in accordance with the 2012 Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves (the JORC Code 2012). The classification categories of Measured, Indicated and Inferred under the JORC Code (2012) are equivalent to the CIM categories of the same names (CIM, 2014). For the purpose of satisfying 'reasonable prospects for eventual extraction' (JORC Code 2012), open pit Mineral Resources are reported above optimised open pit shells developed with actual and estimated operating costs and a long-term gold price assumption of US$2,100 per ounce, with the exception of Nyanzaga reported at US$2,000 per ounce. Underground Mineral Resources at CMA are constrained to below the CMA Stage 3 pit design and reported at a 1.5 g/t Au cut-off. Underground Mineral Resources at Edikan are constrained to a depth of 600 mRL at Esuajah South and are all exclusive of open pit Mineral Resources. Technical Reports associated with these Mineral Resources, have been prepared in accordance with NI 43-101 for the following operations: Nyanzaga Gold Project, Tanzania, NI 43-101 Technical Report, dated 10 June 2025 Yaouré Operations, Côte d'Ivoire, NI 43-101 Technical Report, dated 18 December 2023 Sissingué Operations, Côte d'Ivoire, NI 43-101 Technical Report, dated 29 May 2015 Edikan Operations, Ghana, NI 43-101 Technical Report, dated 6 April 2022 These reports can be found on Perseus's website at and on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) website Perseus's Ore Reserve Estimate CRITERIA FOR ORE RESERVE CLASSIFICATION All Ore Reserves are reported in accordance with the JORC Code (2012) and are reported by category, deposit and type, above variable cut-off grades. The classification categories of Proved and Probable under the JORC Code (2012) are equivalent to the CIM categories Proven and Probable respectively (CIM, 2010). The Ore Reserve is classified as Proved and Probable corresponding to the Mineral Resource classifications of M&I and considering other factors where relevant. The deposits' geological models are well constrained. The Ore Reserve classification is considered appropriate given the nature of the deposits, the moderate grade variability, drilling density, structural complexity, confidence in input parameters based on operational experience and mining history. It was therefore considered appropriate to use Measured Mineral Resources as a basis for Proved Ore Reserves and Indicated Mineral Resources as a basis for Probable Ore Reserves. No Inferred Mineral Resources were included in Ore Reserve estimate with the exception of 2.8 koz of incidental Inferred which is included in the CMA underground development and is not considered material to the Ore Reserve. Technical Disclosure: All Mineral Reserves and Mineral Resources other than the Foreign/Historical Estimates were calculated as of 30 June 2025 and have been calculated and prepared in accordance with the standards set out in the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves dated December 2012 (the 'JORC Code') and in accordance with National Instrument 43-101 of the Canadian Securities Administrators ('NI 43-101'). The JORC Code is the accepted reporting standard for the Australian Stock Exchange Limited ('ASX'). The definitions of Ore Reserves and Mineral Resources as set forth in the JORC Code (2012) have been reconciled to the definitions set forth in the CIM Definition Standards. If the Mineral Reserves and Mineral Resources were estimated in accordance with the definitions in the JORC Code, there would be no substantive difference in such Mineral Reserves and Mineral Resources. Competent Person Statement: The information in this report that relates to Mineral Resources is based on, and fairly represents, information and supporting documentation prepared by Daniel Saunders, a Competent Person who is a Fellow of The Australasian Institute of Mining and Metallurgy. Mr Saunders is a full-time employee of Perseus Mining Limited. Mr Saunders has sufficient experience, which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken, to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'' and to qualify as a 'Qualified Person' under National Instrument 43-101 – Standards of Disclosure for Mineral Projects ('NI 43-101'). Mr Saunders consents to the inclusion in the report of the matters based on his information in the form and context in which it appears. The information in this report that relates to Ore Reserves is based on information compiled by Mr Adrian Ralph, a Competent Person who is a Fellow of The Australasian Institute of Mining and Metallurgy. Mr Ralph is a full-time employee of Perseus Mining Limited. Mr Ralph has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activities which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves' and a Qualified Person as defined in NI 43-101. Mr Ralph consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The Company confirms that the material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Edikan Gold Mine, Ghana' dated 6 April 2022, 'Technical Report — Yaouré Gold Project, Côte d'Ivoire' dated 18 December 2023, 'Technical Report — Sissingué Gold Project, Côte d'Ivoire' dated 29 May 2015, and 'Technical Report — Nyanzaga Gold Project, Tanzania' dated 10 June 2025 continue to information in this report that relates to the Mineral Resources and Probable Reserves of the Block 14 Project was first reported by the Company in a market announcement 'Perseus Enters into Agreement to Acquire Orca Gold Inc.' released on 28 February 2022. The Company confirms it is not in possession of any new information or data relating to those estimates that materially impacts of the reliability of the estimate of the Company's ability to verify the estimate as a Mineral Resource or Ore Reserve in accordance with Appendix 5A (JORC Code) and the information in that in that original market release continues to apply and have not materially changed. These estimates are prepared in accordance with Canadian National Instrument 43-101 standards and have not been reported in accordance with the JORC Code. A competent person has not done sufficient work to classify the resource in accordance with the JORC Code and it is uncertain that following evaluation and/or further exploration work that the estimate will be able to be reported as a Mineral Resource or Ore Reserve in accordance with the JORC Code. Mr Saunders and Mr Ralph have reviewed this press release and all technical information regarding Orca's NI 43-101 Foreign/historical estimate and this information is approved by Adrian Ralph and Daniel Saunders, each a Qualified Person for the purposes of NI 43-101. Caution Regarding Forward Looking Information: This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company's publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws. ASX/TSX CODE: PRUCAPITAL STRUCTURE:Ordinary shares: 1,350,988,737Performance rights: 9,328,134REGISTERED OFFICE:Level 2437 Roberts RoadSubiaco WA 6008Telephone: +61 8 6144 DIRECTORS:Rick MenellNon-Executive ChairmanJeff QuartermaineManaging Director & CEO Amber BanfieldNon-Executive DirectorElissa CorneliusNon-Executive DirectorDan LougherNon-Executive DirectorJohn McGloinNon-Executive DirectorJames RutherfordNon-Executive Director CONTACTS:Jeff QuartermaineManaging Director & FormanInvestor Relations+61 484 036 RyanMedia+61 420 582 These estimates including the tables set out below have been prepared by Orca in accordance with Canadian National Instrument 43-101 standards and have not been reported in accordance with the JORC Code. A competent person has not done sufficient work to classify the resource in accordance with the JORC Code and it is uncertain that following evaluation and/or further exploration work that the estimate will be able to be reported as a mineral resource or ore reserve in accordance with the JORC Code. Orca Ore Reserve and Mineral Resource figures are stated on 100% basis. Attachment 20250821 TSX Annual Resources and Reserves Statement_finalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
